We are live on
!
Find out more
VP
Vitruvian Partners Portfolio holdings
AUM
$112M
1-Year Est. Return
2.02%
This Fund
S&P 500
This Quarter
Est. Return
+16.03%
1 Year Est. Return
+2.02%
3 Year Est. Return
+35.84%
5 Year Est. Return
+18.92%
10 Year Est. Return
–
AUM
$394M
AUM Growth
+$40.9M
(+12%)
Cap. Flow
-$5.98M
Cap. Flow
% of AUM
-1.52%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
1
Reduced
–
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Progyny
PGNY
|
+$2.67M |
| 2 |
Xometry
XMTR
|
+$909K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
+$8M |
| 2 |
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
|
+$1.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 46.58% |
| 2 | Consumer Discretionary | 45.12% |
| 3 | Healthcare | 6.78% |
| 4 | Industrials | 1.52% |
Similar funds
RTM
JE
GW
SPWM
OCA
APFP
FCU
DM
Vitruvian Partners's Q4 2023 Portfolio in Review
As of Q4 2023, Vitruvian Partners held 11 positions worth $394M, up 12% from $353M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Vitruvian Partners's Q4 2023 filing shows 1 new, 1 increased and 2 closed positions. Its largest new stake was Progyny: 79,530 shares worth $2.96M. The largest sale was Farfetch Limited Class A Ordinary Shares, an estimated $8M.
By sector, the portfolio is most concentrated in Technology at 47% of assets, up from 44% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Vitruvian Partners's largest Q4 2023 buy was Progyny: 79,530 shares worth $2.96M.
- Vitruvian Partners added most to Xometry in Q4 2023, an estimated $909K increase.
- Vitruvian Partners fully exited Farfetch Limited Class A Ordinary Shares in Q4 2023, selling an estimated $8M.
- Vitruvian Partners's ten largest holdings make up 100% of its $394M portfolio in Q4 2023.
- Vitruvian Partners opened 1 new position and closed 2 in Q4 2023.
- Vitruvian Partners's portfolio value rose 12% quarter-over-quarter to $394M.
Based on Vitruvian Partners's 13F filing for Q4 2023, filed 9 Feb 2024.